The memorandum also mentioned a number of specific instances where an extension would not be available:     'Patents that claim pharmaceutical substances when produced by a particular process (product by process claims) will not be eligible unless that process involves the use of recombinant DNA technology. 55 Mr Caine next referred to the requirement under s 70(2)(a) that a patent disclose and include within the scope of the claims a pharmaceutical substance per se . Section 70(2)(b) is of no relevance. HIS HONOUR: Yes, I follow. 598197 ("the Patent"). 103 That takes me to the Interpharma Review Proceeding.